Hormone therapy: Evolving concepts

Current Opinion in Rheumatology

Volumn 15, Issue 4, 2003, Pages 464-468

  Hendrix, Susan L ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PLACEBO; SEX HORMONE;

ADRENERGIC SYSTEM; BREAST CANCER; CANCER RISK; CHRONIC DISEASE; CLINICAL PRACTICE; COLORECTAL CARCINOMA; DISEASE SEVERITY; FOLLOW UP; HEART INFARCTION; HORMONAL THERAPY; HUMAN; LUNG EMBOLISM; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MENOPAUSE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLICATION; RANDOMIZATION; REVIEW; RISK FACTOR; STROKE; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; WOMEN'S HEALTH;

EID: 0038434057     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200307000-00015     Document Type: Review

References (20)

1. The Merck Manual. New York, NY: Merck & Co.; 1899.
2. Wilson RA. The roles of estrogen and progesterone in breast and genital cancer. J Am Med Assoc 1962, 182:327-331.
3. Wilson RA: Feminine Forever. New York, NY: M. Evans and Co.; 1966.
4. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002,288:321-333. The National Institutes of Health (NIH) established the Women's Health Initiative (WHI) in 1991 to address the most common causes of death, disability, and impaired quality of life in postmenopausal women. The WHI will address cardiovascular disease, cancer, and osteoporosis. The WHI a 15-year, multimillion-dollar endeavor, and one of the largest US prevention studies of its kind. The three major components of the WHI are (1) a randomized controlled clinical trial of promising but unproven approaches to prevention; (2) an observational study to identify predictors of disease; and (3) a study of community approaches to developing healthful behaviors.
5. The Women's Health Initiative Study Group: Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998, 19:61-109.
6. Stampfer M, Colditz G: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991, 20:47-63.
7. Grady D, Rubin SM, Petitti DB, et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992, 117:1016-1037.
8. Rijpkema AH, van der Sanden AA, Ruijs AH: Effects of postmenopausal estrogen-progesterone therapy on serum lipids and lipoproteins: a review. Maturitas 1990, 12:259-285.
9. Adams MR, Kaplan JR, Manuck SB, et al.: Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1990, 10:1051-1057.
10. Weiss NS, Ure CL, Ballard JH, et al.: Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980, 303:1195-1198.
11. Genant HK, Baylink DJ, Gallagher JC, et al.: Effect of estrone sulfate on postmenopausal bone loss. Obstet Gynecol 1990, 76:579-584.
12. Steinberg KK, Thacker SB, Smith SJ, et al.: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991, 265:1985-1990.
13. Gerhardsson de VM: London S. Reproductive factors, exogenous female hormones, and colorectal cancer by subsite. Cancer Causes Control 1992, 3:355-360.
14. Kolata G: Interviewed by New York Times writer, Gina Kolata, for article "Replacing Hormone Therapy", 'Week in Review' section, p 2, Sunday, October 27, 2002. The New York Times.October 27, 2002.
15. FDA fact sheet. April 4, 2003. Available at http://www.fda.gov/bbs/topics/factsheets/2003/fs1.html.
16. Wyeth-Ayerst per Shay Swiss, Wyeth-Ayerst Woman's Health field representative: St. Davids, PA.
17. Gass M, Liu J, Rebar RW: The effect of low-dose conjugated equine estrogens and cyclic MPA on bone density. Maturitas 2002, 41:143-147.
18. Lindsay R, Gallagher JC, Kleerekoper M, et al.: Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002, 287:2668-2276.
19. Greenspan SL, Emkey RD, Bone HG, et al.: Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002, 137:875-883. This study gives important information regarding bone loss seen after withdrawal of estrogen therapy but not after withdrawal of alendronate or combination alendronate/estrogen therapy.
20. Barrett-Connor E, Hendrix SL, Ettinger B, et al.: Best clinical practice: a comprehensive approach. International position paper on women's health and menopause: a comprehensive approach: National Heart, Lung, and Blood Institute, Office of Women's Health, Giovanni Lorenzini Medical Science Foundation. NIH publication no. 02-3284, 2002, 271-288. This international and multidisciplinary monograph is based on extensive international review and evaluation of the scientific evidence for current clinical practices as presented in the published literature. It represents the culmination of 7 years of cooperation between the National Heart, Lung, and Blood Institute (NHLBI) and the Giovanni Lorenzini Medical Science Foundation (Milan, Italy and Houston, TX) in a public/private partnership in the development and cosponsorship of four international conferences on Women's Health and Menopause since the mid-1990s. The first three conferences were held in Italy, and the most recent one was held in May 2001 in Washington, DC. The last two conferences were also cosponsored by the Office of Research on Women's Health (ORWH), National Institutes of Health (NIH). These conferences have addressed not only cardiovascular disease, but also other health problems, such as cancer, osteoporosis, and Alzheimer's disease, as well as the use and impact of hormone replacement therapy.